Aberrant distribution and function of plasmacytoid dendritic cells in patients with ankylosing spondylitis are associated with unfolded protein response

Kaohsiung J Med Sci. 2020 Jun;36(6):441-449. doi: 10.1002/kjm2.12184. Epub 2020 Jan 21.

Abstract

Although human leucocyte antigen (HLA)-B27 is strongly associated with ankylosing spondylitis (AS), the association of unfolded protein response (UPR) induced by HLA-B27 misfolding in AS remains controversial. Since dendritic cells (DCs) are crucial in induction of AS in HLA-B27-transgenic rats, and plasmacytoid DCs (pDCs) belong to one type of DCs, we here aim to study the relevance of pDCs and UPR in AS. Peripheral pDCs were isolated from 27 HLA-B27(+) AS patients and 37 controls. The bone marrow (BM) and synovium of inflamed hips from AS patients and controls were obtained. We found a significantly higher frequency of pDCs in the peripheral blood, BM, or inflamed synovium of hips, which is associated with the enhanced expression of pDC trafficking molecules, CCR6 and CCL20 in the synovium of AS patients. Functional analysis further revealed that several inflammatory cytokines, including TNFα, IL-6, and IL-23, secreted by pDCs were significantly increased in AS patients as compared with those in controls. Remarkably, protein kinase RNA-like endoplasmic reticulum kinase (PERK) pathway in UPR was up-regulated in pDCs of AS patients. Notably, PERK inhibitor treatment significantly inhibited the enhanced cytokine production by pDCs of AS patients. Further, the extent of PERK activation was significantly associated with the increased disease severity of AS patients. Our data uncover the aberrant distribution and function of pDCs in AS patients. The up-regulated PERK pathway in UPR of pDCs not only contributes to enhanced cytokine production of pDCs, but also is associated with increased disease activity of AS patients.

Keywords: HLA-B27; ankylosing spondylitis; cytokine; plasmacytoid dendritic cells; unfolded protein response.

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Bone Marrow Cells / immunology
  • Bone Marrow Cells / pathology
  • Case-Control Studies
  • Cell Count
  • Chemokine CCL20 / genetics
  • Chemokine CCL20 / immunology
  • Dendritic Cells / immunology*
  • Dendritic Cells / pathology
  • HLA-B27 Antigen / genetics*
  • HLA-B27 Antigen / immunology
  • Hip
  • Humans
  • Immunophenotyping
  • Indoles / pharmacology
  • Interleukin-23 / genetics
  • Interleukin-23 / immunology
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Protein Kinase Inhibitors / pharmacology
  • Receptors, CCR6 / genetics
  • Receptors, CCR6 / immunology
  • Severity of Illness Index
  • Signal Transduction
  • Spondylitis, Ankylosing / genetics
  • Spondylitis, Ankylosing / immunology*
  • Spondylitis, Ankylosing / pathology
  • Synovial Membrane / immunology
  • Synovial Membrane / pathology
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / immunology
  • Unfolded Protein Response*
  • eIF-2 Kinase / antagonists & inhibitors
  • eIF-2 Kinase / genetics*
  • eIF-2 Kinase / immunology

Substances

  • 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine
  • CCL20 protein, human
  • CCR6 protein, human
  • Chemokine CCL20
  • HLA-B27 Antigen
  • IL6 protein, human
  • Indoles
  • Interleukin-23
  • Interleukin-6
  • Protein Kinase Inhibitors
  • Receptors, CCR6
  • Tumor Necrosis Factor-alpha
  • EIF2AK3 protein, human
  • eIF-2 Kinase
  • Adenine